PRINCIPIA FUND

FACTSHEET AT 31 JULY 2021

The Fund aims to earn a higher long-term return than the average of the world's developed equity markets, as represented by the iShares MSCI World UCITS ETF. The investment philosophy is value oriented. Investments are selected after implementing detailed fundamental research, with the objective of finding opportunities where there is a large discrepancy between price and intrinsic value. The Fund will likely differ materially from the performance benchmark in order to achieve its objective.

Price Size Minimum Dilution Levy Dealing Management Fee

> 3 Months Management BV

Performance Chart (A class)¹



Commentary

The largest contributor to performance was BAE Systems (BAE). BAE is a UK listed defence company with a strong presence in several key global defence markets. The business benefits from relationships forged with governments over decades. In some programs they are the sole supplier with no available alternatives. The shares performed strongly in July as the company reported results that exceeded market expectations. At the current price, BAE is trading on a consensus dividend yield of 4.3%, and a consensus price to earnings of 12.3x.

The largest detractor from performance was Atos. Atos is a European based IT services provider with a make-up similar to Accenture or the service side of IBM. A large part of the business is comprised of recurring revenue streams built around long-standing relationships with large corporations. There have been several negative headlines recently, but we believe the main concern the market appears to have is that Atos' business model will be impaired by the rapid shift of IT environments to the cloud. While the current technology landscape is particularly disruptive and fast changing, we believe that IT service providers like Atos are unlikely to get displaced as their role is not to compete with emerging technology but rather to utilize it for their clients. They therefore naturally evolve to change their service offering as older technologies get commoditized. At the current price, Atos is trading on a consensus dividend yield of 2.1%, a consensus price to earnings of 10.6x and a price to estimated normalised earnings of 6.1x.

Geographic Exposure			% of NAV
United States			20.3
Canada			3.6
North America			23.8
Korea			5.4
Greater China			11.3
Other			0.0
Asia ex-Japan			16.7
United Kingdom			21.1
Europe ex-UK			25.4
Europe			46.5
Japan			8.5
Other			1.3
Cash			0.0
Sector Exposure			% of NAV
Consumer Discretionary			9.9
Consumer Staples			13.2
Energy			8.5
Financials			14.3
Health Care			17.8
Industrials			6.8
Technology			5.1
Materials			8.0
Real Estate			0.0
Communication Services			10.8
Utilities			1.6
Cash			0.0
Top 10 Holdings			% of NAV
Sanofi	5.3	AIG	3.9
China Mobile	5.2	GlaxoSmithKline	3.7
BAT	4.9	BAE Systems	3.6
Honda Motor	4.2	Société BIC	3.1
Tesco	4.1	UBS	3.0
			Privium Fund www.privi



-				
	Returns (% net)	Fund	MSCI World (V) ²	MSCI World
	1 month	-1.02	0.52	2.00
	YTD	18.01	18.98	19.66
	1 year	35.84	34.53	35.66
	3 years	21.80	22.12	48.71
	Portfolio Statistics ³		Fund	MSCI World
	Median Market Cap (\$		35.7	105.5
	Weighted Avg. Marke	t Cap (\$bn)	74.0	408.4
	Median P/E (FY1)		11.4	20.0
	Median P/B (FY1)		1.3	2.7
	Median D/Y (FY1)		3.0	2.0
	Number of securities		51	1591
	Active Share		95.2%	-
	Top 5 Contributors	(MTD)		%
	BAE Systems			0.35
	WM Morrison			0.33
L				
	Oracle			0.30
	Oracle UBS			0.30 0.21
	UBS Tesco			0.21 0.17
	UBS Tesco Bottom 5 Contribut	ors (MTD)		0.21 0.17
	UBS Tesco Bottom 5 Contribut Atos	ors (MTD)		0.21 0.17 % -0.29
	UBS Tesco Bottom 5 Contribut Atos Astellas Pharma	ors (MTD)		0.21 0.17 % -0.29 -0.25
	UBS Tesco Bottom 5 Contribut Atos Astellas Pharma NOV	ors (MTD)		0.21 0.17 -0.29 -0.25 -0.23
	UBS Tesco Bottom 5 Contribut Atos Astellas Pharma NOV Schlumberger	ors (MTD)		0.21 0.17 -0.29 -0.25 -0.23 -0.23
	UBS Tesco Bottom 5 Contribut Atos Astellas Pharma NOV	ors (MTD)		0.21 0.17 -0.29 -0.25 -0.23
	UBS Tesco Bottom 5 Contribut Atos Astellas Pharma NOV Schlumberger Luk Fook Liquidity Analysis	ors (MTD)		0.21 0.17 -0.29 -0.25 -0.23 -0.23 -0.16 % of NAV
	UBS Tesco Bottom 5 Contribut Atos Astellas Pharma NOV Schlumberger Luk Fook Liquidity Analysis 1 Day	ors (MTD)		0.21 0.17 -0.29 -0.25 -0.23 -0.23 -0.16 % of NAV 100
	UBS Tesco Bottom 5 Contribut Atos Astellas Pharma NOV Schlumberger Luk Fook Liquidity Analysis 1 Day 5 Days	ors (MTD)		0.21 0.17 -0.29 -0.25 -0.23 -0.23 -0.16 % of NAV 100 100
	UBS Tesco Bottom 5 Contribut Atos Astellas Pharma NOV Schlumberger Luk Fook Liquidity Analysis 1 Day	ors (MTD)		0.21 0.17 -0.29 -0.25 -0.23 -0.23 -0.16 % of NAV 100

100

NOTICES

Do not run any unnecessary risk. Read the Key Investor Information Document. This communication is neither an offer to sell nor a solicitation to invest. Past performance is not indicative of future results. The value of investments and any income generated may go down as well as up and is not guaranteed. Privium Fund Management B.V. is authorized and regulated by the Dutch Authority for the Financial Markets (<u>www.afm.nl</u>) as an Alternative Investment Fund Manager. The Fund and its manager, Privium Fund Management B.V., are held in the register of Dutch Authority for the Financial Markets. The prospectus of the Fund and the Key Investor Information Document can be downloaded via the website of the Fund Manager, <u>www.priviumfund.com</u>. The performance overviews shown in this communication have been carefully composed by Privium Fund Management B.V. No rights can be derived from this communication.

Performance Chart¹

Principia Strategy refers to the same strategy run in a trading account, measured one year prior to launch. The performance of the account has been calculated by Custom House and accounts for all costs and fees.

MSCI World (V)²

Refers to the MSCI World Value Index

Portfolio Statistics³

Source: Principia Fund/Bloomberg. Portfolio statistic data is calculated intra-month at the time of publishing this report. Median P/E and P/B metrrics are based on consensus data. Active share data is calulated once per quarter.